Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Post by Amorfixon Nov 11, 2020 11:00pm
480 Views
Post# 31882750

Greed & Incompetence

Greed & IncompetenceThere is only one question and that being is the stock price higher or lower then when these guys came on the scene and the answer is LOWER. They did incompetent financings, diluted the hell out of the shares and stold money, what more do you need to see. Make no mistake Elliott is in this for himself and treats this like a private Company. He has made misrepresentations to shareholders (Documented) that may be heading to a U.S. Judge to see if he can talk his way out of his misdeeds. No, if it takes a proxy war to get him out, then so be it, he is a detriment to the Company and this Board needs an overhaul badly. I wonder if he did a corporate agreement in the past then asked the Board to approve it after the fact so he would not be in trouble with the SEC, I guess we will find out.
<< Previous
Bullboard Posts
Next >>